Halozyme Therapeutics, Inc. has announced interim results from a proof of concept Phase I/II clinical trial evaluating the activity and local tolerability of HTI-501, an investigational biologic, for use in

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field